

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 May 2005 (06.05.2005)

PCT

(10) International Publication Number  
**WO 2005/039569 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/4196**,  
C07D 249/12, 401/04, A61P 13/10

(21) International Application Number:  
PCT/EP2004/011101

(22) International Filing Date: 5 October 2004 (05.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
03023701.0 18 October 2003 (18.10.2003) EP

(71) Applicant (for all designated States except US): **BAYER HEALTHCARE AG** [DE/DE]; 51368 Leverkusen (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAUSER, Marcus** [DE/DE]; Claudiusweg 3, 42115 Wuppertal (DE). **KRÜGER, Joachim** [DE/DE]; Goltzheimer Platz 4, 40474 Düsseldorf (DE). **MEIER, Heinrich** [DE/DE]; Claudiusweg 3, 42115 Wuppertal (DE). **VÖHRINGER, Verena** [DE/DE]; Am Hochsitz 17, 42113 Wuppertal (DE). **BEYREUTHER, Bettina** [DE/DE]; Weiherstr. 6, 40219 Düsseldorf (DE). **MOGI, Muneto** [JP/JP]; 5-10-57-102, Daianji, Nara-shi, Nara 630-8133 (JP). **MARUMO, Makiko** [JP/JP]; 4-9-307, Minami-machi, Nara-shi, Nara 631-0824 (JP). **TSUNO, Naoki** [JP/JP]; 135-1-102 Aono-cho, Nara-shi, Nara 631-0841 (JP). **SHIMIZU, Haruka** [JP/JP]; B-202, 88 Aono-cho, Nara-shi, Nara 631-0841 (JP). **FUJISHIMA, Hiroshi** [JP/JP]; 3-23-25, Sakyo, Nara-shi, Nara 631-0801 (JP). **YUASA, Hiroaki** [JP/JP]; 4-2-4-D101, Kunimidai, Kizo-cho, Soraku-gun, Kyoto 619-0216 (JP). **HAYASHI,**

Mayumi [JP/JP]; 1-5-14-313, Horai, Nara-shi, Nara 631-0845 (JP). **UMEDA, Masaomi** [JP/JP]; 2-840-156, Sahodai, Nara-shi, Nara 630-8105 (JP). **IWATA, Atsuko** [JP/JP]; 7-14-704, Soegawa-cho, Sanjo, Nara-shi, Nara 630-8127 (JP).

(74) Common Representative: **BAYER HEALTHCARE AG**; Law and Patents, Patents and Licensing, 51368 Leverkusen (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 5-SUBSTITUTED 2-(PHENYLMETHYL) THIO-4-PHENYL-4H-1,2,4-TRIAZOLE DERIVATIVES AND RELATED COMPOUNDS AS GABA-AGONISTS FOR THE TREATMENT OF URINARY INCONTINENCE AND RELATED DISEASES



(57) Abstract: This invention relates to phenyltriazole derivatives of the formula (I) and salts thereof which is useful as an active ingredient of pharmaceutical preparations : (I) wherein R<sup>1</sup> represents alkyl optionally substituted or 3-8 membered saturated or unsaturated ring optionally substituted, R<sup>2</sup> represents -COR<sup>21</sup>, -(CH<sub>2</sub>)<sub>n</sub>-R<sup>21</sup> or tert-butyl, X represents CR<sup>10</sup>R<sup>11</sup>, NR<sup>12</sup>, S, O, SO<sub>2</sub>, or SO wherein R<sup>10</sup>, R<sup>11</sup> and R<sup>12</sup> independently represent hydrogen or methyl. The other substituents are as defined in the claims. The phenyltriazole derivatives of the present invention have an excellent activity as GABA<sub>B</sub> agonist and are useful for the prophylaxis and treatment of diseases associated with GABA<sub>B</sub> activity, in particular for the treatment of overactive bladder, urinary

incontinence such as urge urinary incontinence, benign prostatic hyperplasia (BPH), chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algasia, or nerve injury.